For Forest Labs, One Key To Life After Lexapro May Lie In The COPD Market
This article was originally published in The Pink Sheet Daily
Executive Summary
In their first-ever R&D day for investors, execs discussed pipeline candidates that are intended to guide the firm through the Lexapro patent expiration.
You may also be interested in...
Forest Prepares For A Pair Of Launches, As Lexapro Generics Inch Closer
Forest expects SG&A spending to be heaviest in the fourth quarter, topping $325 million spent in the second quarter on upcoming launches.
Forest Prepares For A Pair Of Launches, As Lexapro Generics Inch Closer
Forest expects SG&A spending to be heaviest in the fourth quarter, topping $325 million spent in the second quarter on upcoming launches.
Good Showing For Nycomed's COPD Drug Daxas
Reports in the Aug. 27 Lancet look good for the novel phosphodiesterase-4 inhibitor, under consideration by U.S. and EU regulators.